TrialRheumatology (Oxford, England)2020

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.

Désirée van der Heijde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.